MiR-34c downregulation leads to SOX4 overexpression and cisplatin resistance in nasopharyngeal carcinoma
Background A major cause of disease-related death in nasopharyngeal carcinoma (NPC) is the development of distant metastasis (DM) despite combination chemoradiotherapy treatment. We previously identified and validated a four microRNA (miRNA) signature that is prognostic for DM. In this study, charac...
Saved in:
| Published in: | BMC cancer Vol. 20; no. 1; pp. 597 - 13 |
|---|---|
| Main Authors: | , , , , , , , , |
| Format: | Journal Article |
| Language: | English |
| Published: |
London
BioMed Central
26.06.2020
BioMed Central Ltd Springer Nature B.V BMC |
| Subjects: | |
| ISSN: | 1471-2407, 1471-2407 |
| Online Access: | Get full text |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| Abstract | Background
A major cause of disease-related death in nasopharyngeal carcinoma (NPC) is the development of distant metastasis (DM) despite combination chemoradiotherapy treatment. We previously identified and validated a four microRNA (miRNA) signature that is prognostic for DM. In this study, characterization of a key component of this signature, miR-34c, revealed its role in chemotherapy resistance.
Methods
Two hundred forty-six NPC patient biopsy samples were subject to comprehensive miRNA profiling and immunohistochemistry (IHC). Two human normal nasopharyngeal cell lines (immortalized; NP69 and NP460), as well as the NPC cell line C666–1, were used for miR-34c gain-of-function and loss-of-function experiments. Signaling pathways were assessed using quantitative real-time PCR (qRT-PCR) and Western blot. Cell viability was measured using the ATPlite assay.
Results
MiR-34c was downregulated in NPC patient samples, and confirmed in vitro to directly target SOX4, a master regulator of epithelial-to-mesenchymal transition (EMT). MiR-34c downregulation triggered EMT-representative changes in NP69 and NP460 whereby Snail, ZEB1, CDH2, and SOX2 were upregulated, while Claudin-1 and CDH1 were downregulated. Phenotypically, inhibition of miR-34c led to cisplatin resistance, whereas miR-34c over-expression sensitized NPC cells to cisplatin. TGFβ1 decreased miR-34c and increased SOX4 expression in vitro. The TGFβ receptor 1 inhibitor SB431542 reduced SOX4 expression and increased cisplatin sensitivity. Finally, IHC revealed that lower SOX4 expression was associated with improved overall survival in chemotherapy-treated NPC patients.
Conclusion
miR-34c is downregulated in NPC. Repression of miR-34c was shown to increase SOX4 expression, which leads to cisplatin resistance, while TGFβ1 was found to repress miR-34c expression. Taken together, our study demonstrates that inhibition of the TGFβ1 pathway could be a strategy to restore cisplatin sensitivity in NPC. |
|---|---|
| AbstractList | Abstract Background A major cause of disease-related death in nasopharyngeal carcinoma (NPC) is the development of distant metastasis (DM) despite combination chemoradiotherapy treatment. We previously identified and validated a four microRNA (miRNA) signature that is prognostic for DM. In this study, characterization of a key component of this signature, miR-34c, revealed its role in chemotherapy resistance. Methods Two hundred forty-six NPC patient biopsy samples were subject to comprehensive miRNA profiling and immunohistochemistry (IHC). Two human normal nasopharyngeal cell lines (immortalized; NP69 and NP460), as well as the NPC cell line C666–1, were used for miR-34c gain-of-function and loss-of-function experiments. Signaling pathways were assessed using quantitative real-time PCR (qRT-PCR) and Western blot. Cell viability was measured using the ATPlite assay. Results MiR-34c was downregulated in NPC patient samples, and confirmed in vitro to directly target SOX4, a master regulator of epithelial-to-mesenchymal transition (EMT). MiR-34c downregulation triggered EMT-representative changes in NP69 and NP460 whereby Snail, ZEB1, CDH2, and SOX2 were upregulated, while Claudin-1 and CDH1 were downregulated. Phenotypically, inhibition of miR-34c led to cisplatin resistance, whereas miR-34c over-expression sensitized NPC cells to cisplatin. TGFβ1 decreased miR-34c and increased SOX4 expression in vitro. The TGFβ receptor 1 inhibitor SB431542 reduced SOX4 expression and increased cisplatin sensitivity. Finally, IHC revealed that lower SOX4 expression was associated with improved overall survival in chemotherapy-treated NPC patients. Conclusion miR-34c is downregulated in NPC. Repression of miR-34c was shown to increase SOX4 expression, which leads to cisplatin resistance, while TGFβ1 was found to repress miR-34c expression. Taken together, our study demonstrates that inhibition of the TGFβ1 pathway could be a strategy to restore cisplatin sensitivity in NPC. A major cause of disease-related death in nasopharyngeal carcinoma (NPC) is the development of distant metastasis (DM) despite combination chemoradiotherapy treatment. We previously identified and validated a four microRNA (miRNA) signature that is prognostic for DM. In this study, characterization of a key component of this signature, miR-34c, revealed its role in chemotherapy resistance. Two hundred forty-six NPC patient biopsy samples were subject to comprehensive miRNA profiling and immunohistochemistry (IHC). Two human normal nasopharyngeal cell lines (immortalized; NP69 and NP460), as well as the NPC cell line C666-1, were used for miR-34c gain-of-function and loss-of-function experiments. Signaling pathways were assessed using quantitative real-time PCR (qRT-PCR) and Western blot. Cell viability was measured using the ATPlite assay. MiR-34c was downregulated in NPC patient samples, and confirmed in vitro to directly target SOX4, a master regulator of epithelial-to-mesenchymal transition (EMT). MiR-34c downregulation triggered EMT-representative changes in NP69 and NP460 whereby Snail, ZEB1, CDH2, and SOX2 were upregulated, while Claudin-1 and CDH1 were downregulated. Phenotypically, inhibition of miR-34c led to cisplatin resistance, whereas miR-34c over-expression sensitized NPC cells to cisplatin. TGF[beta]1 decreased miR-34c and increased SOX4 expression in vitro. The TGF[beta] receptor 1 inhibitor SB431542 reduced SOX4 expression and increased cisplatin sensitivity. Finally, IHC revealed that lower SOX4 expression was associated with improved overall survival in chemotherapy-treated NPC patients. miR-34c is downregulated in NPC. Repression of miR-34c was shown to increase SOX4 expression, which leads to cisplatin resistance, while TGF[beta]1 was found to repress miR-34c expression. Taken together, our study demonstrates that inhibition of the TGF[beta]1 pathway could be a strategy to restore cisplatin sensitivity in NPC. A major cause of disease-related death in nasopharyngeal carcinoma (NPC) is the development of distant metastasis (DM) despite combination chemoradiotherapy treatment. We previously identified and validated a four microRNA (miRNA) signature that is prognostic for DM. In this study, characterization of a key component of this signature, miR-34c, revealed its role in chemotherapy resistance. Two hundred forty-six NPC patient biopsy samples were subject to comprehensive miRNA profiling and immunohistochemistry (IHC). Two human normal nasopharyngeal cell lines (immortalized; NP69 and NP460), as well as the NPC cell line C666-1, were used for miR-34c gain-of-function and loss-of-function experiments. Signaling pathways were assessed using quantitative real-time PCR (qRT-PCR) and Western blot. Cell viability was measured using the ATPlite assay. MiR-34c was downregulated in NPC patient samples, and confirmed in vitro to directly target SOX4, a master regulator of epithelial-to-mesenchymal transition (EMT). MiR-34c downregulation triggered EMT-representative changes in NP69 and NP460 whereby Snail, ZEB1, CDH2, and SOX2 were upregulated, while Claudin-1 and CDH1 were downregulated. Phenotypically, inhibition of miR-34c led to cisplatin resistance, whereas miR-34c over-expression sensitized NPC cells to cisplatin. TGFβ1 decreased miR-34c and increased SOX4 expression in vitro. The TGFβ receptor 1 inhibitor SB431542 reduced SOX4 expression and increased cisplatin sensitivity. Finally, IHC revealed that lower SOX4 expression was associated with improved overall survival in chemotherapy-treated NPC patients. miR-34c is downregulated in NPC. Repression of miR-34c was shown to increase SOX4 expression, which leads to cisplatin resistance, while TGFβ1 was found to repress miR-34c expression. Taken together, our study demonstrates that inhibition of the TGFβ1 pathway could be a strategy to restore cisplatin sensitivity in NPC. A major cause of disease-related death in nasopharyngeal carcinoma (NPC) is the development of distant metastasis (DM) despite combination chemoradiotherapy treatment. We previously identified and validated a four microRNA (miRNA) signature that is prognostic for DM. In this study, characterization of a key component of this signature, miR-34c, revealed its role in chemotherapy resistance.BACKGROUNDA major cause of disease-related death in nasopharyngeal carcinoma (NPC) is the development of distant metastasis (DM) despite combination chemoradiotherapy treatment. We previously identified and validated a four microRNA (miRNA) signature that is prognostic for DM. In this study, characterization of a key component of this signature, miR-34c, revealed its role in chemotherapy resistance.Two hundred forty-six NPC patient biopsy samples were subject to comprehensive miRNA profiling and immunohistochemistry (IHC). Two human normal nasopharyngeal cell lines (immortalized; NP69 and NP460), as well as the NPC cell line C666-1, were used for miR-34c gain-of-function and loss-of-function experiments. Signaling pathways were assessed using quantitative real-time PCR (qRT-PCR) and Western blot. Cell viability was measured using the ATPlite assay.METHODSTwo hundred forty-six NPC patient biopsy samples were subject to comprehensive miRNA profiling and immunohistochemistry (IHC). Two human normal nasopharyngeal cell lines (immortalized; NP69 and NP460), as well as the NPC cell line C666-1, were used for miR-34c gain-of-function and loss-of-function experiments. Signaling pathways were assessed using quantitative real-time PCR (qRT-PCR) and Western blot. Cell viability was measured using the ATPlite assay.MiR-34c was downregulated in NPC patient samples, and confirmed in vitro to directly target SOX4, a master regulator of epithelial-to-mesenchymal transition (EMT). MiR-34c downregulation triggered EMT-representative changes in NP69 and NP460 whereby Snail, ZEB1, CDH2, and SOX2 were upregulated, while Claudin-1 and CDH1 were downregulated. Phenotypically, inhibition of miR-34c led to cisplatin resistance, whereas miR-34c over-expression sensitized NPC cells to cisplatin. TGFβ1 decreased miR-34c and increased SOX4 expression in vitro. The TGFβ receptor 1 inhibitor SB431542 reduced SOX4 expression and increased cisplatin sensitivity. Finally, IHC revealed that lower SOX4 expression was associated with improved overall survival in chemotherapy-treated NPC patients.RESULTSMiR-34c was downregulated in NPC patient samples, and confirmed in vitro to directly target SOX4, a master regulator of epithelial-to-mesenchymal transition (EMT). MiR-34c downregulation triggered EMT-representative changes in NP69 and NP460 whereby Snail, ZEB1, CDH2, and SOX2 were upregulated, while Claudin-1 and CDH1 were downregulated. Phenotypically, inhibition of miR-34c led to cisplatin resistance, whereas miR-34c over-expression sensitized NPC cells to cisplatin. TGFβ1 decreased miR-34c and increased SOX4 expression in vitro. The TGFβ receptor 1 inhibitor SB431542 reduced SOX4 expression and increased cisplatin sensitivity. Finally, IHC revealed that lower SOX4 expression was associated with improved overall survival in chemotherapy-treated NPC patients.miR-34c is downregulated in NPC. Repression of miR-34c was shown to increase SOX4 expression, which leads to cisplatin resistance, while TGFβ1 was found to repress miR-34c expression. Taken together, our study demonstrates that inhibition of the TGFβ1 pathway could be a strategy to restore cisplatin sensitivity in NPC.CONCLUSIONmiR-34c is downregulated in NPC. Repression of miR-34c was shown to increase SOX4 expression, which leads to cisplatin resistance, while TGFβ1 was found to repress miR-34c expression. Taken together, our study demonstrates that inhibition of the TGFβ1 pathway could be a strategy to restore cisplatin sensitivity in NPC. Background A major cause of disease-related death in nasopharyngeal carcinoma (NPC) is the development of distant metastasis (DM) despite combination chemoradiotherapy treatment. We previously identified and validated a four microRNA (miRNA) signature that is prognostic for DM. In this study, characterization of a key component of this signature, miR-34c, revealed its role in chemotherapy resistance. Methods Two hundred forty-six NPC patient biopsy samples were subject to comprehensive miRNA profiling and immunohistochemistry (IHC). Two human normal nasopharyngeal cell lines (immortalized; NP69 and NP460), as well as the NPC cell line C666-1, were used for miR-34c gain-of-function and loss-of-function experiments. Signaling pathways were assessed using quantitative real-time PCR (qRT-PCR) and Western blot. Cell viability was measured using the ATPlite assay. Results MiR-34c was downregulated in NPC patient samples, and confirmed in vitro to directly target SOX4, a master regulator of epithelial-to-mesenchymal transition (EMT). MiR-34c downregulation triggered EMT-representative changes in NP69 and NP460 whereby Snail, ZEB1, CDH2, and SOX2 were upregulated, while Claudin-1 and CDH1 were downregulated. Phenotypically, inhibition of miR-34c led to cisplatin resistance, whereas miR-34c over-expression sensitized NPC cells to cisplatin. TGF[beta]1 decreased miR-34c and increased SOX4 expression in vitro. The TGF[beta] receptor 1 inhibitor SB431542 reduced SOX4 expression and increased cisplatin sensitivity. Finally, IHC revealed that lower SOX4 expression was associated with improved overall survival in chemotherapy-treated NPC patients. Conclusion miR-34c is downregulated in NPC. Repression of miR-34c was shown to increase SOX4 expression, which leads to cisplatin resistance, while TGF[beta]1 was found to repress miR-34c expression. Taken together, our study demonstrates that inhibition of the TGF[beta]1 pathway could be a strategy to restore cisplatin sensitivity in NPC. Keywords: miR-34c, SOX4, TGF[beta]1, EMT, Nasopharyngeal cancer, Cisplatin Background A major cause of disease-related death in nasopharyngeal carcinoma (NPC) is the development of distant metastasis (DM) despite combination chemoradiotherapy treatment. We previously identified and validated a four microRNA (miRNA) signature that is prognostic for DM. In this study, characterization of a key component of this signature, miR-34c, revealed its role in chemotherapy resistance. Methods Two hundred forty-six NPC patient biopsy samples were subject to comprehensive miRNA profiling and immunohistochemistry (IHC). Two human normal nasopharyngeal cell lines (immortalized; NP69 and NP460), as well as the NPC cell line C666–1, were used for miR-34c gain-of-function and loss-of-function experiments. Signaling pathways were assessed using quantitative real-time PCR (qRT-PCR) and Western blot. Cell viability was measured using the ATPlite assay. Results MiR-34c was downregulated in NPC patient samples, and confirmed in vitro to directly target SOX4, a master regulator of epithelial-to-mesenchymal transition (EMT). MiR-34c downregulation triggered EMT-representative changes in NP69 and NP460 whereby Snail, ZEB1, CDH2, and SOX2 were upregulated, while Claudin-1 and CDH1 were downregulated. Phenotypically, inhibition of miR-34c led to cisplatin resistance, whereas miR-34c over-expression sensitized NPC cells to cisplatin. TGFβ1 decreased miR-34c and increased SOX4 expression in vitro. The TGFβ receptor 1 inhibitor SB431542 reduced SOX4 expression and increased cisplatin sensitivity. Finally, IHC revealed that lower SOX4 expression was associated with improved overall survival in chemotherapy-treated NPC patients. Conclusion miR-34c is downregulated in NPC. Repression of miR-34c was shown to increase SOX4 expression, which leads to cisplatin resistance, while TGFβ1 was found to repress miR-34c expression. Taken together, our study demonstrates that inhibition of the TGFβ1 pathway could be a strategy to restore cisplatin sensitivity in NPC. Background A major cause of disease-related death in nasopharyngeal carcinoma (NPC) is the development of distant metastasis (DM) despite combination chemoradiotherapy treatment. We previously identified and validated a four microRNA (miRNA) signature that is prognostic for DM. In this study, characterization of a key component of this signature, miR-34c, revealed its role in chemotherapy resistance. Methods Two hundred forty-six NPC patient biopsy samples were subject to comprehensive miRNA profiling and immunohistochemistry (IHC). Two human normal nasopharyngeal cell lines (immortalized; NP69 and NP460), as well as the NPC cell line C666–1, were used for miR-34c gain-of-function and loss-of-function experiments. Signaling pathways were assessed using quantitative real-time PCR (qRT-PCR) and Western blot. Cell viability was measured using the ATPlite assay. Results MiR-34c was downregulated in NPC patient samples, and confirmed in vitro to directly target SOX4, a master regulator of epithelial-to-mesenchymal transition (EMT). MiR-34c downregulation triggered EMT-representative changes in NP69 and NP460 whereby Snail, ZEB1, CDH2, and SOX2 were upregulated, while Claudin-1 and CDH1 were downregulated. Phenotypically, inhibition of miR-34c led to cisplatin resistance, whereas miR-34c over-expression sensitized NPC cells to cisplatin. TGFβ1 decreased miR-34c and increased SOX4 expression in vitro. The TGFβ receptor 1 inhibitor SB431542 reduced SOX4 expression and increased cisplatin sensitivity. Finally, IHC revealed that lower SOX4 expression was associated with improved overall survival in chemotherapy-treated NPC patients. Conclusion miR-34c is downregulated in NPC. Repression of miR-34c was shown to increase SOX4 expression, which leads to cisplatin resistance, while TGFβ1 was found to repress miR-34c expression. Taken together, our study demonstrates that inhibition of the TGFβ1 pathway could be a strategy to restore cisplatin sensitivity in NPC. |
| ArticleNumber | 597 |
| Audience | Academic |
| Author | Shi, Wei Yip, Kenneth W. Bruce, Jeff P. Liu, Fei-Fei Petit, Valentin Tsao, Sai W. Law, Jacqueline H. Teng, Mona Bissey, Pierre-Antoine |
| Author_xml | – sequence: 1 givenname: Pierre-Antoine surname: Bissey fullname: Bissey, Pierre-Antoine organization: Princess Margaret Cancer Centre, University Health Network – sequence: 2 givenname: Mona surname: Teng fullname: Teng, Mona organization: Department of Medical Biophysics, University of Toronto – sequence: 3 givenname: Jacqueline H. surname: Law fullname: Law, Jacqueline H. organization: Department of Medical Biophysics, University of Toronto – sequence: 4 givenname: Wei surname: Shi fullname: Shi, Wei organization: Princess Margaret Cancer Centre, University Health Network – sequence: 5 givenname: Jeff P. surname: Bruce fullname: Bruce, Jeff P. organization: Princess Margaret Cancer Centre, University Health Network – sequence: 6 givenname: Valentin surname: Petit fullname: Petit, Valentin organization: LabEx DEVweCAN, Université de Lyon – sequence: 7 givenname: Sai W. surname: Tsao fullname: Tsao, Sai W. organization: School of Biomedical Sciences, Li Ka Shing Faculty of Medicine, University of Hong Kong – sequence: 8 givenname: Kenneth W. surname: Yip fullname: Yip, Kenneth W. organization: Princess Margaret Cancer Centre, University Health Network – sequence: 9 givenname: Fei-Fei orcidid: 0000-0003-4344-6486 surname: Liu fullname: Liu, Fei-Fei email: Fei-Fei.Liu@rmp.uhn.on.ca organization: Princess Margaret Cancer Centre, University Health Network, Department of Medical Biophysics, University of Toronto, Radiation Medicine Program, Princess Margaret Cancer Centre, University Health Network, Department of Radiation Oncology, University of Toronto |
| BackLink | https://www.ncbi.nlm.nih.gov/pubmed/32586280$$D View this record in MEDLINE/PubMed |
| BookMark | eNp9kktr3DAUhU1JaR7tH-iiGAqlXTjVy5a8KYTQx0BKIGmhOyFL8owGjzSR7DTNr-_1TNKMQwleyL76zvHV1TnM9nzwNsteY3SMsag-JkyEKAtEUIE4Eri4fZYdYMZxQRjiezvv-9lhSkuEMBdIvMj2KSlFRQQ6yBbf3UVBmc5N-O2jnQ-d6l3weWeVSXkf8svzXywP1zbam3W0KY2byptcu7QeWZ9D1aVeeW1z-PIqhfVCxT9-blWXaxW182GlXmbPW9Ul--puPcp-fvn84_RbcXb-dXZ6clZoTkVfYGQNgb4rVJfMNLxqUE1LrRU3NaMEcVI3TcWMbQkqW0MV1oYxQdq2Upw0lh5ls62vCWop19GtoBcZlJObQohzqWLvdGclZVWJaoOM1TXjpm2QRqTChIOxqRsBXp-2XuuhWVmjre-j6iam0x3vFnIeriWnWDBRg8H7O4MYrgaberlySduuU96GIUnCsMAUVYgD-vYRugxD9DAqoAjjnKISPVBzBQdwvg3wXz2aypPxQnHJCAbq-D8UPMaunIYQtQ7qE8GHiQCY3t70czWkJGeXF1P23Q67gEvuFyl0wxibNAXf7E7v39juwweA2AI6hpSibaV2_SZ-0K7rJEZyzLnc5lxCzuUm5_IWpOSR9N79SRHdihLAEM_4MOInVH8BDxUN2g |
| CitedBy_id | crossref_primary_10_1016_j_biopha_2022_113490 crossref_primary_10_1007_s13237_024_00499_x crossref_primary_10_1158_1078_0432_CCR_22_0979 crossref_primary_10_2147_OTT_S292259 crossref_primary_10_2174_1874467215666220415131344 crossref_primary_10_1016_j_anl_2021_04_013 crossref_primary_10_1007_s10555_023_10152_9 crossref_primary_10_1007_s10565_022_09738_w crossref_primary_10_1007_s12032_025_03004_9 crossref_primary_10_1016_j_biopha_2023_114336 crossref_primary_10_1515_med_2023_0632 crossref_primary_10_1016_j_bbadis_2024_167357 crossref_primary_10_2147_CMAR_S336265 crossref_primary_10_1186_s12957_024_03441_2 crossref_primary_10_1016_j_ejphar_2022_175212 crossref_primary_10_3389_fonc_2022_1008027 crossref_primary_10_1016_j_semcancer_2023_02_003 crossref_primary_10_3389_fonc_2024_1299249 crossref_primary_10_1097_MD_0000000000025028 crossref_primary_10_1002_ptr_7305 crossref_primary_10_1017_erm_2021_15 |
| Cites_doi | 10.1016/j.bbrc.2017.10.014 10.1093/bioinformatics/bts635 10.1007/s12094-015-1337-4 10.1128/JVI.01183-10 10.1016/j.radonc.2010.09.023 10.1038/s41418-018-0152-1 10.1371/journal.ppat.1000170 10.1016/j.ccr.2013.04.020 10.7150/thno.21713 10.7554/eLife.27706 10.1158/0008-5472.CAN-05-3055 10.1186/s13046-016-0292-4 10.1111/cas.13780 10.1007/s13277-016-5060-8 10.1074/jbc.M111.300863 10.1038/nature13305 10.1038/sj.cdd.4400783 10.1016/j.critrevonc.2016.11.017 10.1093/jnci/djq258 10.1371/journal.pone.0052804 10.1016/S1044579X0200086X 10.1002/ijc.22107 10.1002/ijc.22032 10.1158/0008-5472.CAN-12-1045 10.1016/j.biopha.2017.10.163 10.1038/mtna.2014.47 10.1038/nm.2284 10.18632/oncotarget.3382 10.1038/cddis.2014.582 10.1007/s10637-016-0407-y 10.4161/cbt.11.5.14550 10.1038/onc.2010.215 10.1016/j.cytogfr.2009.10.004 10.1007/s10549-017-4139-2 10.1158/0008-5472.CAN-15-2321 10.1158/0008-5472.CAN-15-1868 10.1186/1471-2105-12-323 10.3390/cancers10080247 10.1111/pcmr.12483 10.1038/onc.2012.506 10.1038/srep23932 10.3390/cancers11030395 10.1111/ijlh.12566 10.1158/0008-5472.CAN-16-2355 10.1038/s41419-018-0778-4 10.18632/oncotarget.6483 10.1074/mcp.M116.064451 10.18632/oncotarget.3005 10.1016/j.radonc.2012.08.001 10.1186/s12885-016-2430-y 10.1371/journal.pone.0067128 10.1038/cdd.2011.31 10.1002/ijc.25269 10.1016/j.biopha.2018.06.115 10.1038/s41389-018-0050-x 10.1002/jcb.26865 10.1200/JCO.2015.60.9347 10.1016/j.cell.2015.01.043 10.1158/0008-5472.CAN-13-1942 10.1186/s12885-015-1875-8 10.1016/j.febslet.2012.03.023 10.1038/cddis.2015.290 10.1038/oncsis.2017.25 10.1155/2015/658141 10.1016/j.bbacli.2016.11.001 10.1006/meth.2001.1262 10.1002/(SICI)1097-0215(19990820)84:4<396::AID-IJC11>3.0.CO;2-# 10.1093/annonc/mdx770 10.3892/or.2017.5641 10.1038/cdd.2009.56 10.1002/cncr.0679 10.1016/j.virusres.2018.11.001 10.1016/j.ccr.2012.07.023 10.1007/s13277-015-4374-2 10.1016/j.stem.2009.08.018 10.1158/1078-0432.CCR-09-2166 10.3390/ijms19071901 10.1042/BSR20180375 10.1016/j.radonc.2014.02.003 10.1007/s00280-013-2108-y 10.1016/S0167-4889(02)00208-2 10.1186/1471-2407-6-227 10.1016/S1470-2045(15)70126-9 10.1038/pcan.2013.25 10.1158/1078-0432.CCR-17-1959 10.1016/j.ejca.2010.10.026 |
| ContentType | Journal Article |
| Copyright | The Author(s) 2020 COPYRIGHT 2020 BioMed Central Ltd. 2020. This work is licensed under http://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License. |
| Copyright_xml | – notice: The Author(s) 2020 – notice: COPYRIGHT 2020 BioMed Central Ltd. – notice: 2020. This work is licensed under http://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License. |
| DBID | C6C AAYXX CITATION CGR CUY CVF ECM EIF NPM ISR 3V. 7TO 7X7 7XB 88E 8FI 8FJ 8FK ABUWG AFKRA AZQEC BENPR CCPQU DWQXO FYUFA GHDGH H94 K9. M0S M1P PHGZM PHGZT PIMPY PJZUB PKEHL PPXIY PQEST PQQKQ PQUKI PRINS 7X8 5PM DOA |
| DOI | 10.1186/s12885-020-07081-z |
| DatabaseName | Springer Nature OA Free Journals CrossRef Medline MEDLINE MEDLINE (Ovid) MEDLINE MEDLINE PubMed Gale In Context: Science ProQuest Central (Corporate) Oncogenes and Growth Factors Abstracts Health & Medical Collection ProQuest Central (purchase pre-March 2016) Medical Database (Alumni Edition) Hospital Premium Collection Hospital Premium Collection (Alumni Edition) ProQuest Central (Alumni) (purchase pre-March 2016) ProQuest Central (Alumni) ProQuest Central UK/Ireland ProQuest Central Essentials ProQuest Central (subscription) ProQuest One ProQuest Central Health Research Premium Collection (UHCL Subscription) Health Research Premium Collection (Alumni) AIDS and Cancer Research Abstracts ProQuest Health & Medical Complete (Alumni) ProQuest Health & Medical Collection Medical Database ProQuest Central Premium ProQuest One Academic Publicly Available Content Database ProQuest Health & Medical Research Collection ProQuest One Academic Middle East (New) ProQuest One Health & Nursing ProQuest One Academic Eastern Edition (DO NOT USE) ProQuest One Academic (retired) ProQuest One Academic UKI Edition ProQuest Central China MEDLINE - Academic PubMed Central (Full Participant titles) DOAJ Directory of Open Access Journals |
| DatabaseTitle | CrossRef MEDLINE Medline Complete MEDLINE with Full Text PubMed MEDLINE (Ovid) Publicly Available Content Database Oncogenes and Growth Factors Abstracts ProQuest One Academic Middle East (New) ProQuest Central Essentials ProQuest Health & Medical Complete (Alumni) ProQuest Central (Alumni Edition) ProQuest One Community College ProQuest One Health & Nursing ProQuest Central China ProQuest Central ProQuest Health & Medical Research Collection Health Research Premium Collection Health and Medicine Complete (Alumni Edition) ProQuest Central Korea Health & Medical Research Collection AIDS and Cancer Research Abstracts ProQuest Central (New) ProQuest Medical Library (Alumni) ProQuest One Academic Eastern Edition ProQuest Hospital Collection Health Research Premium Collection (Alumni) ProQuest Hospital Collection (Alumni) ProQuest Health & Medical Complete ProQuest Medical Library ProQuest One Academic UKI Edition ProQuest One Academic ProQuest One Academic (New) ProQuest Central (Alumni) MEDLINE - Academic |
| DatabaseTitleList | MEDLINE MEDLINE - Academic Publicly Available Content Database |
| Database_xml | – sequence: 1 dbid: DOA name: DOAJ Directory of Open Access Journals url: https://www.doaj.org/ sourceTypes: Open Website – sequence: 2 dbid: NPM name: PubMed url: http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 3 dbid: PIMPY name: Publicly Available Content Database url: http://search.proquest.com/publiccontent sourceTypes: Aggregation Database |
| DeliveryMethod | fulltext_linktorsrc |
| Discipline | Medicine |
| EISSN | 1471-2407 |
| EndPage | 13 |
| ExternalDocumentID | oai_doaj_org_article_346509d0dec947dfb0c0261275fdd9b8 PMC7318489 A628015421 32586280 10_1186_s12885_020_07081_z |
| Genre | Journal Article |
| GeographicLocations | France United States--US |
| GeographicLocations_xml | – name: United States--US – name: France |
| GrantInformation_xml | – fundername: Health & Medical Research Fund grantid: #04151726 – fundername: The Ministry of Health and Long-Term Care grantid: None – fundername: The Campbell Family Institute for Cancer Research grantid: None – fundername: The Mariano Elia Chair in Head & Neck Cancer Research – fundername: Canadian Institutes for Health Research grantid: #PJT – 153289 – fundername: The Peter and Shelagh Godsoe Chair in Radiation Medicine – fundername: The Princess Margaret Cancer Centre Head & Neck Translational Program, with philanthropic funds from the Wharton Family, Joe’s Team, and Gordon Tozer grantid: None – fundername: Research Grant Council grantid: C7027-16G – fundername: Canadian Institutes for Health Research grantid: #PJT - 153289 – fundername: The Princess Margaret Cancer Centre Head & Neck Translational Program, with philanthropic funds from the Wharton Family, Joe's Team, and Gordon Tozer grantid: None – fundername: ; grantid: None – fundername: ; – fundername: ; grantid: #PJT – 153289 – fundername: ; grantid: #04151726 – fundername: ; grantid: C7027-16G |
| GroupedDBID | --- 0R~ 23N 2WC 53G 5VS 6J9 6PF 7X7 88E 8FI 8FJ AAFWJ AAJSJ AASML AAWTL ABDBF ABUWG ACGFO ACGFS ACIHN ACMJI ACPRK ACUHS ADBBV ADRAZ ADUKV AEAQA AENEX AFKRA AFPKN AHBYD AHMBA AHYZX ALMA_UNASSIGNED_HOLDINGS AMKLP AMTXH AOIJS BAPOH BAWUL BCNDV BENPR BFQNJ BMC BPHCQ BVXVI C6C CCPQU CS3 DIK DU5 E3Z EAD EAP EAS EBD EBLON EBS EMB EMK EMOBN ESX F5P FYUFA GROUPED_DOAJ GX1 HMCUK HYE IAO IHR IHW INH INR ISR ITC KQ8 M1P M48 M~E O5R O5S OK1 OVT P2P PGMZT PHGZM PHGZT PIMPY PJZUB PPXIY PQQKQ PROAC PSQYO PUEGO RBZ RNS ROL RPM RSV SBL SOJ SV3 TR2 TUS U2A UKHRP W2D WOQ WOW XSB AAYXX AFFHD CITATION ALIPV CGR CUY CVF ECM EIF NPM 3V. 7TO 7XB 8FK AZQEC DWQXO H94 K9. PKEHL PQEST PQUKI PRINS 7X8 5PM |
| ID | FETCH-LOGICAL-c738t-10ed214760954db76b0935cca7d94320729bb64def205fd3a1cd4482ff6a72be3 |
| IEDL.DBID | DOA |
| ISICitedReferencesCount | 27 |
| ISICitedReferencesURI | http://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=Summon&SrcAuth=ProQuest&DestLinkType=CitingArticles&DestApp=WOS_CPL&KeyUT=000545718700004&url=https%3A%2F%2Fcvtisr.summon.serialssolutions.com%2F%23%21%2Fsearch%3Fho%3Df%26include.ft.matches%3Dt%26l%3Dnull%26q%3D |
| ISSN | 1471-2407 |
| IngestDate | Fri Oct 03 12:51:35 EDT 2025 Tue Nov 04 01:54:40 EST 2025 Fri Sep 05 14:31:14 EDT 2025 Tue Oct 07 05:40:01 EDT 2025 Tue Nov 11 10:03:35 EST 2025 Tue Nov 04 17:36:41 EST 2025 Thu Nov 13 15:33:57 EST 2025 Thu May 22 21:23:57 EDT 2025 Thu Apr 03 07:07:44 EDT 2025 Sat Nov 29 06:41:55 EST 2025 Tue Nov 18 20:47:25 EST 2025 Sat Sep 06 07:17:36 EDT 2025 |
| IsDoiOpenAccess | true |
| IsOpenAccess | true |
| IsPeerReviewed | true |
| IsScholarly | true |
| Issue | 1 |
| Keywords | TGFβ1 Nasopharyngeal cancer EMT SOX4 Cisplatin miR-34c |
| Language | English |
| License | Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data. |
| LinkModel | DirectLink |
| MergedId | FETCHMERGED-LOGICAL-c738t-10ed214760954db76b0935cca7d94320729bb64def205fd3a1cd4482ff6a72be3 |
| Notes | ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 14 content type line 23 |
| ORCID | 0000-0003-4344-6486 |
| OpenAccessLink | https://doaj.org/article/346509d0dec947dfb0c0261275fdd9b8 |
| PMID | 32586280 |
| PQID | 2424773050 |
| PQPubID | 44074 |
| PageCount | 13 |
| ParticipantIDs | doaj_primary_oai_doaj_org_article_346509d0dec947dfb0c0261275fdd9b8 pubmedcentral_primary_oai_pubmedcentral_nih_gov_7318489 proquest_miscellaneous_2418130607 proquest_journals_2424773050 gale_infotracmisc_A628015421 gale_infotracacademiconefile_A628015421 gale_incontextgauss_ISR_A628015421 gale_healthsolutions_A628015421 pubmed_primary_32586280 crossref_citationtrail_10_1186_s12885_020_07081_z crossref_primary_10_1186_s12885_020_07081_z springer_journals_10_1186_s12885_020_07081_z |
| PublicationCentury | 2000 |
| PublicationDate | 2020-06-26 |
| PublicationDateYYYYMMDD | 2020-06-26 |
| PublicationDate_xml | – month: 06 year: 2020 text: 2020-06-26 day: 26 |
| PublicationDecade | 2020 |
| PublicationPlace | London |
| PublicationPlace_xml | – name: London – name: England |
| PublicationTitle | BMC cancer |
| PublicationTitleAbbrev | BMC Cancer |
| PublicationTitleAlternate | BMC Cancer |
| PublicationYear | 2020 |
| Publisher | BioMed Central BioMed Central Ltd Springer Nature B.V BMC |
| Publisher_xml | – name: BioMed Central – name: BioMed Central Ltd – name: Springer Nature B.V – name: BMC |
| References | C Jiang (7081_CR71) 2017; 38 L Guo (7081_CR15) 2016; 37 X Lin (7081_CR54) 2017; 493 S Cao (7081_CR63) 2016; 7 W Shi (7081_CR69) 2006; 119 W Chen (7081_CR16) 2016; 37 G Misso (7081_CR44) 2014; 3 P Blanchard (7081_CR6) 2015; 16 AW Lee (7081_CR7) 2010; 102 AW Lee (7081_CR10) 2014; 110 PA Bissey (7081_CR12) 2018; 7 Z Wang (7081_CR42) 2011; 11 AB Hui (7081_CR57) 2010; 16 L Zhao (7081_CR67) 2015; 6 F Wang (7081_CR39) 2016; 35 J Chen (7081_CR70) 2016; 18 L Wang (7081_CR32) 2013; 16 B Bilir (7081_CR23) 2016; 76 AW Lee (7081_CR4) 2011; 47 CL Fang (7081_CR33) 2012; 7 CM Lin (7081_CR34) 2013; 8 P Liu (7081_CR28) 2006; 66 C Liu (7081_CR51) 2011; 17 J Xu (7081_CR66) 1999; 84 H Ikushima (7081_CR19) 2009; 5 R Bayraktar (7081_CR50) 2018; 24 KJ Livak (7081_CR59) 2001; 25 RD Ghosh (7081_CR88) 2016; 6 AW Lee (7081_CR5) 2015; 33 H Hermeking (7081_CR45) 2010; 17 SJ Vervoort (7081_CR37) 2018; 7 HM Li (7081_CR56) 2006; 119 J Zhang (7081_CR27) 2012; 72 R Favaro (7081_CR73) 2014; 74 JP Bruce (7081_CR11) 2015; 6 N Raab-Traub (7081_CR2) 2002; 12 G Zou (7081_CR68) 2018; 109 EL Tan (7081_CR64) 2006; 6 SL Tung (7081_CR78) 2017; 6 SJ Vervoort (7081_CR36) 2013; 32 S Boumahdi (7081_CR72) 2014; 511 J Lv (7081_CR80) 2019; 260 SJ Korsmeyer (7081_CR81) 2000; 7 AW Lee (7081_CR9) 2012; 104 J Massagué (7081_CR13) 2012; 586 HI Suzuki (7081_CR18) 2018; 19 X Yuan (7081_CR30) 2017; 2017 W Han (7081_CR29) 2019; 26 S Shi (7081_CR35) 2015; 2015 A Singh (7081_CR75) 2010; 29 TM Yoon (7081_CR26) 2015; 15 G Zhang (7081_CR87) 2018; 97 Q Zhang (7081_CR48) 2017; 7 R Sun (7081_CR24) 2015; 6 N Oshimori (7081_CR14) 2015; 160 P Pinton (7081_CR82) 2011; 18 M Frikha (7081_CR8) 2018; 29 Z Hagman (7081_CR40) 2010; 127 D Wen (7081_CR47) 2017; 77 DQ Yang (7081_CR43) 2017; 39 CX Yang (7081_CR89) 2019; 11 GA Mehta (7081_CR31) 2017; 162 Z Vojtechova (7081_CR58) 2016; 16 B Li (7081_CR61) 2011; 12 N Tiwari (7081_CR25) 2013; 23 J Lacombe (7081_CR46) 2017; 109 AW Lee (7081_CR3) 2011; 98 W Shi (7081_CR62) 2002; 94 N Sivachandran (7081_CR84) 2010; 84 MS Beg (7081_CR85) 2017; 35 H Ikushima (7081_CR20) 2011; 286 Z Liu (7081_CR22) 2018; 42 H Wu (7081_CR79) 2013; 71 A Hata (7081_CR17) 2009; 20 YQ Li (7081_CR38) 2015; 6 S Xiao (7081_CR77) 2018; 120 N Raab-Traub (7081_CR1) 1992; 3 N Sivachandran (7081_CR83) 2008; 4 Y Zhang (7081_CR86) 2018; 9 K Weina (7081_CR21) 2016; 29 SW Tsao (7081_CR55) 2002; 1590 S Velapasamy (7081_CR65) 2018; 10 BD Adams (7081_CR49) 2016; 76 G Huang (7081_CR53) 2018; 106 LO Sousa (7081_CR41) 2016; 6 A Dobin (7081_CR60) 2013; 29 BR Kim (7081_CR74) 2017; 16 P Yang (7081_CR52) 2012; 22 Y Hu (7081_CR76) 2018; 38 |
| References_xml | – volume: 493 start-page: 1464 issue: 4 year: 2017 ident: 7081_CR54 publication-title: Biochem Biophys Res Commun doi: 10.1016/j.bbrc.2017.10.014 – volume: 29 start-page: 15 issue: 1 year: 2013 ident: 7081_CR60 publication-title: Bioinformatics doi: 10.1093/bioinformatics/bts635 – volume: 18 start-page: 65 issue: 1 year: 2016 ident: 7081_CR70 publication-title: Clin Transl Oncol doi: 10.1007/s12094-015-1337-4 – volume: 84 start-page: 11113 issue: 21 year: 2010 ident: 7081_CR84 publication-title: J Virol doi: 10.1128/JVI.01183-10 – volume: 98 start-page: 15 issue: 1 year: 2011 ident: 7081_CR3 publication-title: Radiother Oncol doi: 10.1016/j.radonc.2010.09.023 – volume: 26 start-page: 796 year: 2019 ident: 7081_CR29 publication-title: Cell Death Differ doi: 10.1038/s41418-018-0152-1 – volume: 4 start-page: e1000170 issue: 10 year: 2008 ident: 7081_CR83 publication-title: PLoS Pathog doi: 10.1371/journal.ppat.1000170 – volume: 23 start-page: 768 issue: 6 year: 2013 ident: 7081_CR25 publication-title: Cancer Cell doi: 10.1016/j.ccr.2013.04.020 – volume: 7 start-page: 4777 issue: 19 year: 2017 ident: 7081_CR48 publication-title: Theranostics doi: 10.7150/thno.21713 – volume: 7 start-page: e27706 year: 2018 ident: 7081_CR37 publication-title: Elife doi: 10.7554/eLife.27706 – volume: 66 start-page: 4011 issue: 8 year: 2006 ident: 7081_CR28 publication-title: Cancer Res doi: 10.1158/0008-5472.CAN-05-3055 – volume: 35 start-page: 17 year: 2016 ident: 7081_CR39 publication-title: J Exp Clin Cancer Res doi: 10.1186/s13046-016-0292-4 – volume: 109 start-page: 3416 issue: 11 year: 2018 ident: 7081_CR68 publication-title: Cancer Sci doi: 10.1111/cas.13780 – volume: 37 start-page: 10011 issue: 8 year: 2016 ident: 7081_CR16 publication-title: Tumour Biol doi: 10.1007/s13277-016-5060-8 – volume: 286 start-page: 41434 issue: 48 year: 2011 ident: 7081_CR20 publication-title: J Biol Chem doi: 10.1074/jbc.M111.300863 – volume: 511 start-page: 246 issue: 7508 year: 2014 ident: 7081_CR72 publication-title: Nature doi: 10.1038/nature13305 – volume: 7 start-page: 1166 issue: 12 year: 2000 ident: 7081_CR81 publication-title: Cell Death Differ doi: 10.1038/sj.cdd.4400783 – volume: 109 start-page: 69 year: 2017 ident: 7081_CR46 publication-title: Crit Rev Oncol Hematol doi: 10.1016/j.critrevonc.2016.11.017 – volume: 102 start-page: 1188 issue: 15 year: 2010 ident: 7081_CR7 publication-title: J Natl Cancer Inst doi: 10.1093/jnci/djq258 – volume: 7 issue: 12 year: 2012 ident: 7081_CR33 publication-title: PLoS One doi: 10.1371/journal.pone.0052804 – volume: 12 start-page: 431 issue: 6 year: 2002 ident: 7081_CR2 publication-title: Semin Cancer Biol doi: 10.1016/S1044579X0200086X – volume: 119 start-page: 2467 issue: 10 year: 2006 ident: 7081_CR69 publication-title: Int J Cancer doi: 10.1002/ijc.22107 – volume: 119 start-page: 1567 issue: 7 year: 2006 ident: 7081_CR56 publication-title: Int J Cancer doi: 10.1002/ijc.22032 – volume: 72 start-page: 4597 issue: 17 year: 2012 ident: 7081_CR27 publication-title: Cancer Res doi: 10.1158/0008-5472.CAN-12-1045 – volume: 97 start-page: 736 year: 2018 ident: 7081_CR87 publication-title: Biomed Pharmacother doi: 10.1016/j.biopha.2017.10.163 – volume: 3 start-page: e194 year: 2014 ident: 7081_CR44 publication-title: Mol Ther Nucleic Acids doi: 10.1038/mtna.2014.47 – volume: 17 start-page: 211 issue: 2 year: 2011 ident: 7081_CR51 publication-title: Nat Med doi: 10.1038/nm.2284 – volume: 6 start-page: 9781 issue: 12 year: 2015 ident: 7081_CR67 publication-title: Oncotarget doi: 10.18632/oncotarget.3382 – volume: 6 start-page: e1618 year: 2015 ident: 7081_CR38 publication-title: Cell Death Dis doi: 10.1038/cddis.2014.582 – volume: 35 start-page: 180 issue: 2 year: 2017 ident: 7081_CR85 publication-title: Investig New Drugs doi: 10.1007/s10637-016-0407-y – volume: 11 start-page: 490 issue: 5 year: 2011 ident: 7081_CR42 publication-title: Cancer Biol Ther doi: 10.4161/cbt.11.5.14550 – volume: 29 start-page: 4741 issue: 34 year: 2010 ident: 7081_CR75 publication-title: Oncogene doi: 10.1038/onc.2010.215 – volume: 20 start-page: 517 issue: 5–6 year: 2009 ident: 7081_CR17 publication-title: Cytokine Growth Factor Rev doi: 10.1016/j.cytogfr.2009.10.004 – volume: 162 start-page: 439 issue: 3 year: 2017 ident: 7081_CR31 publication-title: Breast Cancer Res Treat doi: 10.1007/s10549-017-4139-2 – volume: 76 start-page: 927 issue: 4 year: 2016 ident: 7081_CR49 publication-title: Cancer Res doi: 10.1158/0008-5472.CAN-15-2321 – volume: 76 start-page: 1112 issue: 5 year: 2016 ident: 7081_CR23 publication-title: Cancer Res doi: 10.1158/0008-5472.CAN-15-1868 – volume: 12 start-page: 323 year: 2011 ident: 7081_CR61 publication-title: BMC Bioinform doi: 10.1186/1471-2105-12-323 – volume: 10 start-page: 247 issue: 8 year: 2018 ident: 7081_CR65 publication-title: Cancers (Basel) doi: 10.3390/cancers10080247 – volume: 29 start-page: 453 issue: 4 year: 2016 ident: 7081_CR21 publication-title: Pigment Cell Melanoma Res doi: 10.1111/pcmr.12483 – volume: 32 start-page: 3397 issue: 29 year: 2013 ident: 7081_CR36 publication-title: Oncogene doi: 10.1038/onc.2012.506 – volume: 6 start-page: 23932 year: 2016 ident: 7081_CR88 publication-title: Sci Rep doi: 10.1038/srep23932 – volume: 11 start-page: 395 issue: 3 year: 2019 ident: 7081_CR89 publication-title: Cancers (Basel) doi: 10.3390/cancers11030395 – volume: 39 start-page: 42 issue: 1 year: 2017 ident: 7081_CR43 publication-title: Int J Lab Hematol doi: 10.1111/ijlh.12566 – volume: 77 start-page: 3244 issue: 12 year: 2017 ident: 7081_CR47 publication-title: Cancer Res doi: 10.1158/0008-5472.CAN-16-2355 – volume: 9 start-page: 777 issue: 7 year: 2018 ident: 7081_CR86 publication-title: Cell Death Dis doi: 10.1038/s41419-018-0778-4 – volume: 7 start-page: 4252 issue: 4 year: 2016 ident: 7081_CR63 publication-title: Oncotarget doi: 10.18632/oncotarget.6483 – volume: 16 start-page: 1864 issue: 10 year: 2017 ident: 7081_CR74 publication-title: Mol Cell Proteomics doi: 10.1074/mcp.M116.064451 – volume: 6 start-page: 4537 issue: 6 year: 2015 ident: 7081_CR11 publication-title: Oncotarget doi: 10.18632/oncotarget.3005 – volume: 104 start-page: 272 issue: 3 year: 2012 ident: 7081_CR9 publication-title: Radiother Oncol doi: 10.1016/j.radonc.2012.08.001 – volume: 2017 start-page: 6894675 year: 2017 ident: 7081_CR30 publication-title: Biomed Res Int – volume: 16 start-page: 382 year: 2016 ident: 7081_CR58 publication-title: BMC Cancer doi: 10.1186/s12885-016-2430-y – volume: 3 start-page: 297 issue: 5 year: 1992 ident: 7081_CR1 publication-title: Semin Cancer Biol – volume: 8 start-page: e67128 issue: 6 year: 2013 ident: 7081_CR34 publication-title: PLoS One doi: 10.1371/journal.pone.0067128 – volume: 18 start-page: 1450 issue: 9 year: 2011 ident: 7081_CR82 publication-title: Cell Death Differ doi: 10.1038/cdd.2011.31 – volume: 127 start-page: 2768 issue: 12 year: 2010 ident: 7081_CR40 publication-title: Int J Cancer doi: 10.1002/ijc.25269 – volume: 42 start-page: 3395 issue: 6 year: 2018 ident: 7081_CR22 publication-title: Int J Mol Med – volume: 106 start-page: 217 year: 2018 ident: 7081_CR53 publication-title: Biomed Pharmacother doi: 10.1016/j.biopha.2018.06.115 – volume: 7 start-page: 40 issue: 5 year: 2018 ident: 7081_CR12 publication-title: Oncogenesis doi: 10.1038/s41389-018-0050-x – volume: 120 start-page: 2940 issue: 3 year: 2018 ident: 7081_CR77 publication-title: J Cell Biochem doi: 10.1002/jcb.26865 – volume: 33 start-page: 3356 issue: 29 year: 2015 ident: 7081_CR5 publication-title: J Clin Oncol doi: 10.1200/JCO.2015.60.9347 – volume: 160 start-page: 963 issue: 5 year: 2015 ident: 7081_CR14 publication-title: Cell doi: 10.1016/j.cell.2015.01.043 – volume: 74 start-page: 1833 issue: 6 year: 2014 ident: 7081_CR73 publication-title: Cancer Res doi: 10.1158/0008-5472.CAN-13-1942 – volume: 15 start-page: 888 year: 2015 ident: 7081_CR26 publication-title: BMC Cancer doi: 10.1186/s12885-015-1875-8 – volume: 586 start-page: 1953 issue: 14 year: 2012 ident: 7081_CR13 publication-title: FEBS Lett doi: 10.1016/j.febslet.2012.03.023 – volume: 6 start-page: e1990 year: 2015 ident: 7081_CR24 publication-title: Cell Death Dis doi: 10.1038/cddis.2015.290 – volume: 6 start-page: e326 issue: 5 year: 2017 ident: 7081_CR78 publication-title: Oncogenesis doi: 10.1038/oncsis.2017.25 – volume: 2015 start-page: 658141 year: 2015 ident: 7081_CR35 publication-title: Dis Markers doi: 10.1155/2015/658141 – volume: 6 start-page: 159 year: 2016 ident: 7081_CR41 publication-title: BBA Clin doi: 10.1016/j.bbacli.2016.11.001 – volume: 25 start-page: 402 issue: 4 year: 2001 ident: 7081_CR59 publication-title: Methods doi: 10.1006/meth.2001.1262 – volume: 84 start-page: 396 issue: 4 year: 1999 ident: 7081_CR66 publication-title: Int J Cancer doi: 10.1002/(SICI)1097-0215(19990820)84:4<396::AID-IJC11>3.0.CO;2-# – volume: 29 start-page: 731 issue: 3 year: 2018 ident: 7081_CR8 publication-title: Ann Oncol doi: 10.1093/annonc/mdx770 – volume: 38 start-page: 82 issue: 1 year: 2017 ident: 7081_CR71 publication-title: Oncol Rep doi: 10.3892/or.2017.5641 – volume: 17 start-page: 193 issue: 2 year: 2010 ident: 7081_CR45 publication-title: Cell Death Differ doi: 10.1038/cdd.2009.56 – volume: 94 start-page: 1997 issue: 7 year: 2002 ident: 7081_CR62 publication-title: Cancer doi: 10.1002/cncr.0679 – volume: 260 start-page: 1 year: 2019 ident: 7081_CR80 publication-title: Virus Res doi: 10.1016/j.virusres.2018.11.001 – volume: 22 start-page: 291 issue: 3 year: 2012 ident: 7081_CR52 publication-title: Cancer Cell doi: 10.1016/j.ccr.2012.07.023 – volume: 37 start-page: 115 issue: 1 year: 2016 ident: 7081_CR15 publication-title: Tumour Biol doi: 10.1007/s13277-015-4374-2 – volume: 5 start-page: 504 issue: 5 year: 2009 ident: 7081_CR19 publication-title: Cell Stem Cell doi: 10.1016/j.stem.2009.08.018 – volume: 16 start-page: 1129 issue: 4 year: 2010 ident: 7081_CR57 publication-title: Clin Cancer Res doi: 10.1158/1078-0432.CCR-09-2166 – volume: 19 start-page: 1901 issue: 7 year: 2018 ident: 7081_CR18 publication-title: Int J Mol Sci doi: 10.3390/ijms19071901 – volume: 38 start-page: BSR20180375 issue: 3 year: 2018 ident: 7081_CR76 publication-title: Biosci Rep doi: 10.1042/BSR20180375 – volume: 110 start-page: 377 issue: 3 year: 2014 ident: 7081_CR10 publication-title: Radiother Oncol doi: 10.1016/j.radonc.2014.02.003 – volume: 71 start-page: 1159 issue: 5 year: 2013 ident: 7081_CR79 publication-title: Cancer Chemother Pharmacol doi: 10.1007/s00280-013-2108-y – volume: 1590 start-page: 150 issue: 1–3 year: 2002 ident: 7081_CR55 publication-title: Biochim Biophys Acta doi: 10.1016/S0167-4889(02)00208-2 – volume: 6 start-page: 227 year: 2006 ident: 7081_CR64 publication-title: BMC Cancer doi: 10.1186/1471-2407-6-227 – volume: 16 start-page: 645 issue: 6 year: 2015 ident: 7081_CR6 publication-title: Lancet Oncol doi: 10.1016/S1470-2045(15)70126-9 – volume: 16 start-page: 301 issue: 4 year: 2013 ident: 7081_CR32 publication-title: Prostate Cancer Prostatic Dis doi: 10.1038/pcan.2013.25 – volume: 24 start-page: 4225 issue: 17 year: 2018 ident: 7081_CR50 publication-title: Clin Cancer Res doi: 10.1158/1078-0432.CCR-17-1959 – volume: 47 start-page: 656 issue: 5 year: 2011 ident: 7081_CR4 publication-title: Eur J Cancer doi: 10.1016/j.ejca.2010.10.026 |
| SSID | ssj0017808 |
| Score | 2.425307 |
| Snippet | Background
A major cause of disease-related death in nasopharyngeal carcinoma (NPC) is the development of distant metastasis (DM) despite combination... A major cause of disease-related death in nasopharyngeal carcinoma (NPC) is the development of distant metastasis (DM) despite combination chemoradiotherapy... Background A major cause of disease-related death in nasopharyngeal carcinoma (NPC) is the development of distant metastasis (DM) despite combination... Abstract Background A major cause of disease-related death in nasopharyngeal carcinoma (NPC) is the development of distant metastasis (DM) despite combination... |
| SourceID | doaj pubmedcentral proquest gale pubmed crossref springer |
| SourceType | Open Website Open Access Repository Aggregation Database Index Database Enrichment Source Publisher |
| StartPage | 597 |
| SubjectTerms | Antineoplastic agents Benzamides - pharmacology Biomedical and Life Sciences Biomedicine Biopsy Cancer metastasis Cancer Research Carcinoma Cell and molecular biology Cell cycle Cell Line, Tumor Cell viability Chemoradiotherapy Chemoresistance Chemotherapy Cisplatin Cisplatin - pharmacology Cisplatin - therapeutic use Dioxoles - pharmacology Down-Regulation Drug Resistance, Neoplasm - drug effects Drug Resistance, Neoplasm - genetics E-cadherin EMT Epithelial-Mesenchymal Transition - genetics Gene Expression Regulation, Neoplastic - drug effects Growth factors Health Promotion and Disease Prevention Humans Immunohistochemistry Lymphocytes Medicine/Public Health Mesenchyme Metastases Metastasis MicroRNA MicroRNAs MicroRNAs - genetics MicroRNAs - metabolism miR-34c miRNA Nasopharyngeal cancer Nasopharyngeal carcinoma Nasopharyngeal Carcinoma - drug therapy Nasopharyngeal Carcinoma - genetics Nasopharyngeal Carcinoma - mortality Nasopharyngeal Carcinoma - pathology Nasopharyngeal Neoplasms - drug therapy Nasopharyngeal Neoplasms - genetics Nasopharyngeal Neoplasms - mortality Nasopharyngeal Neoplasms - pathology Nasopharynx - pathology Oncology Overexpression Patients Prostate Radiation therapy Research Article RNA-Seq SOX4 SOXC Transcription Factors - genetics Stem cells Surgical Oncology TGFβ1 Throat cancer Transforming Growth Factor beta1 - antagonists & inhibitors Transforming Growth Factor beta1 - metabolism Transforming growth factor-b1 Transforming growth factors |
| SummonAdditionalLinks | – databaseName: ProQuest Central (subscription) dbid: BENPR link: http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwpV3db9QwDI_ghhAvfH8UBhSExANU66Vpkj6hDW0CiR3TDaS9RfnqdtJoj-sdgv312G2uo0Pshcc2rlrHjuPU9s-EvHKFz6yD04lPqU5YyUwirRWJ5m4sfG6Mdm3Xkk9iMpFHR8VB-OHWhLTKtU1sDbWrLf4j38IyBgHqmKfv5t8T7BqF0dXQQuMq2UCkMjYiGzu7k4NpH0cQMpXrUhnJtxqwxhIrktMEVF2Ok7PBdtSi9v9tm__YnC4mTl6Inrab0t6t_2XnNrkZ3NF4u9OfO-SKr-6S6_sh4H6PnOzPpknGbOzgtL7o-taDJONTUI0mXtbx4ecjFmMaqP8ZUmqrWFcutrNmjrRVDHfRRwXliuGq0tg3QS9-ATvwYoutjKr6m75Pvu7tfnn_IQnNGRIrMrkE8-0d9jhCwDrmjOAGQ6qgD8IVLKMISG4MZ86XNM1Ll-mxdXAUpGXJtaDGZw_IqKor_4jEVFjwRLzINXOs0NRwXeS-SLm23Ja-jMh4LSNlA3I5NtA4Ve0JRnLVyVWBXFUrV3UWkTf9M_MOt-NS6h0UfU-JmNvtjXpxrMISVhlDtEGXOm8LJlxpUtsCsAlgzxVGRuQ5Ko7qClh7y6G2OZXoqdJxRF62FIi7UWFiz7FeNY36eDgdEL0ORGUNXFod6iRgrhCqa0C5OaAEw2CHw2vVU8EwNepc7yLyoh_GJzHZrvL1CmnA7YOjZCoi8rBT-H5mMppLfENExGApDKZuOFLNTlrYcgHbB5NFRN6uF835Z_1bNI8v5-IJuUHb5cwTyjfJaLlY-afkmv2xnDWLZ8Ec_Aa2DmiK priority: 102 providerName: ProQuest – databaseName: SpringerLink dbid: RSV link: http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV1Zb9QwELagIMQL9xEoEBASDxCROI7tPBZEBRItaBfQvlmO7bQrFafa7CLor2fGOSDlkOAx8ViJ57TlmW8IeWxLlxsLpxOXUp2wmlWJNEYkmttMuKKqtA1dS96K_X25WJTv-6Kwdsh2H64kg6cOZi358xY8qcRq4jQBNZVZcnKWnINwJ9EcZ_NP492BkKkcymN-O28SggJS_6_--KeAdDpZ8tSNaQhEu5f_bwlXyKV-4xnvdJpylZxx_hq5sNdfrV8nh3vLWZIzE1s4l6-6DvUgs_gIlKCN1008f7dgMSZ8uq998qyPtbexWbbHSOtjeIu7UVCjGJ68xg4JevUNfhA-bLBpkW8-6xvk4-6rDy9fJ30bhsSIXK7BUTuL3YwQmo7ZSvAKL09B8sKWLKcIPV5VnFlX07Soba4zY-HQR-uaa0Erl98kW77x7jaJqTCw53Ci0MyyUtOK67JwZcq14aZ2dUSyQTLK9Bjl2CrjSIWziuSqY6ECFqrAQnUSkafjnOMOoeOv1C9Q4CMlomuHF83qQPXGqnKGuII2tc6UTNi6Sk2AWhOwPFtWMiIPUF1UV6o6-gi1w6nEPSnNIvIoUCDChscUngO9aVv1Zj6bED3pieoGVml0XxEBvEJQrgnl9oQSXICZDg96q3oX1Cqs-xHgv4s0Ig_HYZyJaXXeNRukgQ0eHBpTEZFbnZqPnMlpIfELERETA5iwbjril4cBoFxAoGCyjMizwQx-_NafRXPn38jvkos0WBJPKN8mW-vVxt0j582X9bJd3Q8u4TtKLF4- priority: 102 providerName: Springer Nature |
| Title | MiR-34c downregulation leads to SOX4 overexpression and cisplatin resistance in nasopharyngeal carcinoma |
| URI | https://link.springer.com/article/10.1186/s12885-020-07081-z https://www.ncbi.nlm.nih.gov/pubmed/32586280 https://www.proquest.com/docview/2424773050 https://www.proquest.com/docview/2418130607 https://pubmed.ncbi.nlm.nih.gov/PMC7318489 https://doaj.org/article/346509d0dec947dfb0c0261275fdd9b8 |
| Volume | 20 |
| WOSCitedRecordID | wos000545718700004&url=https%3A%2F%2Fcvtisr.summon.serialssolutions.com%2F%23%21%2Fsearch%3Fho%3Df%26include.ft.matches%3Dt%26l%3Dnull%26q%3D |
| hasFullText | 1 |
| inHoldings | 1 |
| isFullTextHit | |
| isPrint | |
| journalDatabaseRights | – providerCode: PRVADU databaseName: BioMedCentral customDbUrl: eissn: 1471-2407 dateEnd: 99991231 omitProxy: false ssIdentifier: ssj0017808 issn: 1471-2407 databaseCode: RBZ dateStart: 20010101 isFulltext: true titleUrlDefault: https://www.biomedcentral.com/search/ providerName: BioMedCentral – providerCode: PRVAON databaseName: DOAJ Directory of Open Access Journals customDbUrl: eissn: 1471-2407 dateEnd: 99991231 omitProxy: false ssIdentifier: ssj0017808 issn: 1471-2407 databaseCode: DOA dateStart: 20010101 isFulltext: true titleUrlDefault: https://www.doaj.org/ providerName: Directory of Open Access Journals – providerCode: PRVHPJ databaseName: ROAD: Directory of Open Access Scholarly Resources customDbUrl: eissn: 1471-2407 dateEnd: 99991231 omitProxy: false ssIdentifier: ssj0017808 issn: 1471-2407 databaseCode: M~E dateStart: 20010101 isFulltext: true titleUrlDefault: https://road.issn.org providerName: ISSN International Centre – providerCode: PRVPQU databaseName: Health & Medical Collection customDbUrl: eissn: 1471-2407 dateEnd: 99991231 omitProxy: false ssIdentifier: ssj0017808 issn: 1471-2407 databaseCode: 7X7 dateStart: 20090101 isFulltext: true titleUrlDefault: https://search.proquest.com/healthcomplete providerName: ProQuest – providerCode: PRVPQU databaseName: ProQuest Central customDbUrl: eissn: 1471-2407 dateEnd: 99991231 omitProxy: false ssIdentifier: ssj0017808 issn: 1471-2407 databaseCode: BENPR dateStart: 20090101 isFulltext: true titleUrlDefault: https://www.proquest.com/central providerName: ProQuest – providerCode: PRVPQU databaseName: Publicly Available Content Database customDbUrl: eissn: 1471-2407 dateEnd: 99991231 omitProxy: false ssIdentifier: ssj0017808 issn: 1471-2407 databaseCode: PIMPY dateStart: 20090101 isFulltext: true titleUrlDefault: http://search.proquest.com/publiccontent providerName: ProQuest – providerCode: PRVAVX databaseName: Springer customDbUrl: eissn: 1471-2407 dateEnd: 99991231 omitProxy: false ssIdentifier: ssj0017808 issn: 1471-2407 databaseCode: RSV dateStart: 20011201 isFulltext: true titleUrlDefault: https://link.springer.com/search?facet-content-type=%22Journal%22 providerName: Springer Nature |
| link | http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwrV3db9MwELdgIMTLxOfIGCUgJB4gWuo4tvO4oU1MoqVqAZUny7EdVmm4U9Mi2F_PnZOWZQh44aWS44vi3p3Pd_Ld7wh5YQuXGQvRiUupTljFykQaIxLNbV-4vCy1DV1L3onhUE6nxehSqy_MCWvggRvG7WcMMd5sap0pmLBVmZoAeyXyytqiDGW-4PWsg6n2_kDIVK5LZCTfr8EKS6xEThNQcdlPLjrHUEDr_90mXzqUriZMXrk1DYfR8R2y3XqR8UGz-rvkmvP3yK1Be09-n5wOZuMkYya2EGQvmnbzIID4DCRax8t5PHk_ZTFmb7rvbSasj7W3sZnV50jrY3iKriXoRAwjr7HdgV78gNXAhw12IPLzr_oB-Xh89OHN26TtqZAYkcklWF1nsTUR4swxWwpe4k0oiFHYgmUUccTLkjPrKpoChzPdNxYiOFpVXAtauuwh2fJz7x6RmAoDDoQTuWaWFZqWXBe5K1KuDTeVqyLSX7NYmRZwHPtenKkQeEiuGrEoEIsKYlEXEXm1eee8gdv4K_UhSm5DiVDZ4QEokGoVSP1LgSLyFOWumrrTzYZXB5xKdDBpPyLPAwXCZXjMx_miV3WtTibjDtHLlqiaw780ui1vAF4hwlaHcq9DCfvZdKfXCqhae1IrLOIRYIzzNCLPNtP4JubIeTdfIQ14axABpiIiO42-bjiT0VziFyIiOprcYV13xs9OA9q4AKvPZBGR12ud_7WsP4tm93-I5jG5TcOe5Qnle2RruVi5J-Sm-bac1YseuS6mIvzKHrlxeDQcjXvBCsBodDIYfYbRePLpJ1jaX5E |
| linkProvider | Directory of Open Access Journals |
| linkToHtml | http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMw1V1Lb9NAEB6VFAEX3g9DoQaBOIBVZ73xrg8IlUfVqE2p2iKV07LeXbeRih3ilNL-KH4jM46d4iJ664FjvOM4M_5mZic7D4DnNnGRsRiduJDpgGc8DaQxItCx7QrXS1Ntq6kl62JjQ-7uJptz8KuphaG0ysYmVobaFob-I1-iMgaBcOyFb0ffA5oaRaerzQiNKSzW3PERhmzlm_4HfL8vGFv5uPN-NainCgRGRHKCdsdZGs5Dnda4TUWc0lkgMiJswiNGnbTTNObWZSzsZTbSXWMxhmFZFmvBUhfh916CeY5glx2Y3-wPNr_Mzi2EDGVTmiPjpRKtv6QK6DBA1ZLd4KTl_qopAX_7gj-c4dlEzTOntZUTXLnxv4nvJlyvt9v-8lQ_bsGcy2_DlUGdUHAH9gfDrSDixrfFESrSXj3MzD9A6Jf-pPC3P-1yn9Jc3c86ZTj3dW59MyxHRJv7eJX24Kg8Pn7KNc2F0ONjFB8-2NCoprz4pu_C5wvh8x508iJ3D8BnwuBOy4me5pYnmqWxTnouCWNtYpO5zINugwll6s7sNCDkQFURmozVFEcKcaQqHKkTD17N7hlN-5KcS_2OoDajpJ7i1YVivKdqE6UiTt0UbWidSbiwWRqaqsGcQPZskkoPFgmoalqgO7OMajlmknbirOvBs4qC-orklLi0pw_LUvW3t1pEL2uirEAuja7rQFBW1IqsRbnQokTDZ9rLDdRVbXhLdYpzD57OlulOSibMXXFINLitxVA5FB7cnyrYTDIRajU9wQPRUr2W6Nor-XC_assu0D1ymXjwulHS05_171fz8HwuFuHq6s5gXa33N9YewTVWmZI4YPECdCbjQ_cYLpsfk2E5flKbIh--XrT6_gbWicVN |
| linkToPdf | http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwpV3db9QwDI9goIkXvj8KgxWExAOr1ktzSfo4Pk5MbMe0Abq3KE3S7aSRnq53CPbXY6e9so4PCfHYxlEbx3Zi2f6ZkOc2d5mx4J24lOqElaxIpDEi0dwOhBsWhbaha8meGI_lZJIfnKviD9nuq5BkU9OAKE1-sT2zZaPikm_XYFUlVhanCYisHCRnl8kVhk2D0F8_-tzFEYRM5apU5rfzesdRQO3_1TafO5wuJk5eiJ6GQ2l04_-Xc5Ncby-k8U4jQbfIJedvk_X9NuR-h5zsTw-TjJnYgr8-bzrXw17GpyAcdbyo4qMPExZjIqj71ibV-lh7G5tpPUNaH8NbvKWCeMXw5DV2TtDz7_Cz8GGDzYx89UXfJZ9Gbz--fpe07RkSIzK5AAPuLHY5Qsg6ZgvBCwyqgkQIm7OMIiR5UXBmXUnTYWkzPTAWnEFallwLWrjsHlnzlXcPSEyFgbuIE0PNLMs1LbjOhy5PuTbclK6MyGC1S8q02OXYQuNUBR9GctWwUAELVWChOovIy27OrEHu-Cv1K9z8jhJRt8OLan6sWiVWGUO8QZtaZ3ImbFmkJkCwCViezQsZkU0UHdWUsHa2Q-1wKvGuSgcReRYoEHnDY2rPsV7Wtdo9OuwRvWiJygpWaXRbKQG8QrCuHuVGjxJMg-kPr2RYtaapVlgPJMCuD9OIPO2GcSam23lXLZEGLn7gTKYiIvcbke84k9GhxC9ERPSUoce6_oifngTgcgEHCJN5RLZWKvHzt_68NQ__jXyTrB-8Gam93fH7R-QaDUrFE8o3yNpivnSPyVXzdTGt50-CpfgBSFpqBg |
| openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=MiR-34c+downregulation+leads+to+SOX4+overexpression+and+cisplatin+resistance+in+nasopharyngeal+carcinoma&rft.jtitle=BMC+cancer&rft.au=Bissey%2C+Pierre-Antoine&rft.au=Teng%2C+Mona&rft.au=Law%2C+Jacqueline+H&rft.au=Shi%2C+Wei&rft.date=2020-06-26&rft.pub=BioMed+Central+Ltd&rft.issn=1471-2407&rft.eissn=1471-2407&rft.volume=20&rft.issue=1&rft_id=info:doi/10.1186%2Fs12885-020-07081-z&rft.externalDocID=A628015421 |
| thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=1471-2407&client=summon |
| thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=1471-2407&client=summon |
| thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=1471-2407&client=summon |